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Abstract
Purpose Congenital duodenal obstruction (CDO) is associated with trisomy 21 (T21), or Down’s syndrome, in around a 
third of infants. The aim of this study was to explore the impact of T21 on the epidemiology, management, and outcomes 
of infants with CDO.
Methods Data were prospectively collected from specialist neonatal surgical centres in the United Kingdom over a 12 month 
period from March 2016 using established population-based methodology for all babies with CDO. Infants with T21 were 
compared to those without any chromosomal anomaly.
Results Of 102 infants with CDO that underwent operative repair, T21 was present in 33 [32% (95% CI 23–41%)] babies. 
Cardiac anomalies were more common in those with T21 compared to those without a chromosomal anomaly (91 vs 17%, 
p < 0.001), whereas associated gastrointestinal anomalies were less common in infants with T21 (3 vs 12%, p = 0.03). Surgi-
cal management was not influenced by T21. Time to achieve full enteral feed, need for repeat related surgery, and mortality 
were similar between groups. Infants with T21 had a longer median initial inpatient stay (23 vs 16.5 days, p = 0.02).
Conclusions Infants with T21 have a higher incidence of cardiac anomalies and a longer initial inpatient stay; however, it 
does not change CDO management or outcomes. This information is important for prenatal and postnatal counselling of 
parents of infants with CDO and T21.
Keywords Duodenal atresia · Duodenal stenosis · Down syndrome · Trisomy 21 · Congenital cardiac disease
Introduction
Congenital duodenal obstruction (CDO), due to duodenal 
atresia or stenosis, is seen in 1.22 per 10 000 live births and 
requires surgical restoration of gastrointestinal tract conti-
nuity which usually takes place within the first few days of 
life [1]. Trisomy 21 (T21), or Down’s syndrome, is present 
in around a third of infants with CDO and is, therefore, the 
most commonly associated chromosomal anomaly [1, 2].
In some other neonatal surgical conditions, infants with 
T21 are managed differently than those without T21 pos-
sibly due to concerns about tissue healing. For example, in 
a recent observational study of the management of infants 
with Hirschsprung disease in the United Kingdom (UK), 
infants with T21 were four times more likely to undergo 
enterostomy formation prior to definitive surgical manage-
ment than those without a chromosomal anomaly [3].
Previous, single-centre studies that have explored the 
impact of T21 on the management of CDO have produced 
conflicting data. A study from Thailand found that infants 
with T21 had a higher rate of post-operative complications 
and mortality [4]. However, a UK-based institution reported 
no difference in outcomes of CDO between those with and 
without T21 [2].
Given the conflicting, low-quality, existing evidence on 
this topic the aim of this study was to explore the impact of 
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T21 on the epidemiology, management, and outcomes of 
infants with CDO.
Methods
This analysis was undertaken according to a pre-specified 
protocol using the British Association of Paediatric Sur-
geons Congenital Anomaly Surveillance System. Ethical 
approval was granted by the National Research Ethics Ser-
vice South Central-Oxford A committee (ref: 12/SC/0416).
Case identification
The process of case identification has been described previously 
[1]. Briefly, live born cases of congenital occlusion or narrow-
ing of the duodenum associated with atresia, stenosis, duodenal 
web, or annular pancreas presenting prior to a post-conceptual 
age of 44 completed weeks were prospectively identified over a 
1-year period from 1st March 2016 at all 28 specialist neonatal 
surgical centres in the UK. Cases of duodenal occlusion or nar-
rowing caused by congenital bands associated with malrotation, 
intestinal volvulus, duplication cyst, or malignancy without an 
intrinsic duodenal abnormality were excluded.
Data collection
After a case was identified via a monthly reporting card, a 
data collection form was sent for each case to the specialist 
neonatal surgical centre at day 28 and then 1 year following 
surgical repair. These forms were then returned and data 
were then entered into a database at the National Perinatal 
Epidemiological Unit, Oxford.
For the purpose of this analysis, infants were only 
included if they underwent operative repair, had a confirmed 
diagnosis of T21, or had no other detected chromosomal 
abnormality.
Outcomes
Main outcomes were defined in the study protocol and were 
time to achieve full enteral feeds, use and duration of paren-
teral nutrition, number of central venous catheters (CVCs—
including both peripherally inserted and centrally inserted 
catheters) used, CVC-related complications, anastomotic 
complications, inpatient hospital stay, standardised weight 
gain/loss, and death.
Statistical analysis
Statistical analysis took place using StataSE v15 (Stata-
Corp LLC, Texas, USA). Fisher’s exact test was used for 
categorical data and Chi-squared test was used for cate-
gorical data with more than 2 × 2 analysis. A Mann–Whit-
ney U test was used for continuous data. Data are reported 
as median with range or number with percentage as appro-
priate. p < 0.05 was considered statistically significant.
To calculate standardised weight change, the zanthro 
package for StataSE v15 was used to calculate weight-for-
age z scores using UK World Health Organization term 
and preterm growth reference charts. For infants with 
Down syndrome, the Zemel 2015 weight-for-age growth 
chart was used instead [5]. The weight-for-age z score, 
also known as standard deviation (SD) score, is a measure 
of the SD of weight from the mean value of a reference 
population matched for gestational age and sex [6].
Results
Study population
In the study period, there were 103 babies with CDO and 
102 that underwent operative repair. T21 was present in 33 
[32% (95% CI 23–41%)] infants. In 65 (63%) infants with 
CDO, there was no chromosomal anomaly reported and 
death occurred prior to operative repair once. Additionally, 
there were five (4.9%) babies with chromosomal anoma-
lies other than T21; these were excluded along with the one 
infant who died prior to operative repair. The study popula-
tion, therefore, comprised 33 infants with T21 and 64 infants 
without a chromosomal anomaly. Of those alive at 28 days 
following surgical repair (95/97 infants), follow-up data at 
1 year were available for 76 (80%) infants including 25/33 
(81%) with T21 and 51/64 (80%) with no chromosomal 
anomaly.
Prenatal screening and demographics
Prenatal screening for chromosomal anomalies was under-
taken in 23 (24%) cases using either amniocentesis (n = 17), 
non-invasive prenatal testing of maternal blood (n = 4), 
chorionic villi sampling (n = 1), or microarray compara-
tive genomic hybridisation (n = 1). Out of those tested T21 
was detected in 11 (48%) foetuses. Therefore, the overall 
prenatal detection rate of T21 in CDO was 33% (95% CI 
17–49%). The sex, gestational age at birth, birthweight, 
atresia type, and site of obstruction were all similar between 
those with T21 and those without chromosomal anomaly 
(Table 1).
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Associated anomalies
Other congenital anomalies were present in 93% (31/33) 
of infants with T21 and 50% (32/64) infants without chro-
mosomal anomaly. Three of these anomalies were not 
reported at 28 days, but were reported at 1 year (two with 
atrial septal defects and one with annular pancreas). Car-
diac anomalies were the most frequent and were seen more 
often in those with T21 than those without chromosomal 
anomaly (91 vs 27%, p < 0.001). Other gastrointestinal 
(GI) tract anomalies were more common in those with-
out chromosomal anomaly compared to those with T21 
(Table 2). There were no cases of Hirschsprung disease 
identified in either group.
Anatomy and management of CDO
The type of duodenal atresia or stenosis along with the site 
of obstruction was similar between those with T21 and 
without chromosomal anomaly (Table 1). Age at surgical 
repair, surgical technique used, approach to post-operative 
feeding, and nutritional management were all similar 
between the groups; however, those with T21 had a shorter 
time to commencing enteral feeds post-repair than those 
without (2.5 vs 4 days, p = 0.046).
Outcome
The proportion of infants who had achieved full enteral feeds 
at both 28 days and 1 year following surgical repair was sim-
ilar between those with T21 and those with no chromosomal 
anomaly (Table 3). Overall duration of parenteral nutrition 
(PN) and number of infants experiencing CVC complica-
tions were similar between the two groups.
In total, there were ten post-operative complications, and 
these were small bowel obstruction (n = 3), wound infection 
(n = 2), anastomotic leak (n = 1), chest sepsis requiring intu-
bation (n = 1), wound dehiscence (n = 1), incisional hernia 
(n = 1), and a stitch abscess (n = 1). These complications 
were distributed evenly between those with T21 and infants 
without a chromosomal anomaly (11% vs 13%, p = 1.00). In 
total, there were five repeat laparotomies which were simi-
larly distributed between the two groups of infants (Table 3).
Table 1  Group characteristics 
and management undertaken 
comparing infants with T21 to 
those without a chromosomal 
anomaly
p value in bold indicates statistically significant
T21 trisomy 21, CDO congenital duodenal obstruction, TAT trans-anastomotic tube, PICC peripherally 
inserted central catheter, CVC central venous catheter, PN parenteral nutrition
T21 (n = 33) No chromosomal 
anomaly (n = 64)
p
Male, n (%) 18 (55) 35 (55) 1.00
Gestational age at birth, weeks (range) 36.3 (28.1–39.4) 36.3 (25.6–42.3) 0.61
Birthweight, grams (range) 2290 (800–3730) 2520 (830–4320) 0.38
Prenatal CDO diagnosis, n (%) 24 (73) 32 (50) 0.05
Atresia type, n (%)
  I 15 (45) 24 (38) 0.43
  II 3 (9.1) 2 (3.1)
  III 9 (27.3) 25 (39)
  Not reported or not identified 6 (18.2) 13 (20)
Site of obstruction, n (%)
  Pre-ampullary 6 (18) 19 (30) 0.13
  Post-ampullary 13 (39) 30 (47)
  Not reported or not identified 14 (42) 15 (23)
Age at surgery, days (range) 2 (0–14) 3 (0–75) 0.08
Repair type, n (%)
  Duodenoduodenostomy 24 (75) 49 (77) 0.15
  Duodenojejunostomy 8 (25) 7 (11)
  Membrane incision 0 (0) 1 (1.6)
  Membrane resection 0 (0) 4 (6.3)
  Duodenoplasty 0 (0) 3 (4.7)
TAT used, n (%) 16 (49) 24 (38) 0.38
PICC/CVC used, n (%) 29 (88) 59 (92) 0.48
PN used, n (%) 28 (85) 58 (91) 0.50
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Those with T21 had a longer inpatient stay than those 
without chromosomal anomaly (23 vs 16.5 days, p = 0.02), 
but all infants alive with follow-up at 1 year following surgi-
cal repair had been discharged by this time.
Difference in standardised weight-for-age z scores from 
birth was calculated for the two groups at both 28 days and 
1 year post surgical repair and those with T21 has higher 
z scores than those without chromosomal anomaly at both 
time points (Table 3). There were 6 (7.8%) deaths within 
1 year from causes unrelated to CDO. Although the mortal-
ity rate was higher in infants with T21 (15 vs 4%), this did 
not reach statistical significance, noting the limited statisti-
cal power of this comparison. Two of these deaths occurred 
within 28 days of operative repair.
Discussion
We and others have identified that T21 is present in around 
one-third of infants with CDO [1, 7]. T21 is, therefore, the 
most commonly associated chromosomal anomaly. Since 
it is known that in other conditions managed by paediatric 
surgeons, management differs for those with T21 compared 
to those without a chromosomal anomaly such as T21 [3], 
we aimed to explore the impact of T21 on the epidemiology, 
management, and outcomes of those with CDO. Our key 
finding from this prospective population-based study is that 
we found very little difference in epidemiology and man-
agement and outcomes of these infants with the exceptions 
that infants with T21 were more likely to have CDO diag-
nosed antenatally, more likely to have a cardiac anomaly, and 
less likely to have a GI tract anomaly than infants without 
Table 2  Associated anomalies 
with CDO comparing infants 
with T21 to those without a 
chromosomal anomaly
p values in bold indicate statistically significant
T21 trisomy 21, PDA patent ductus arteriosus, VSD ventricular septal defect, PFO patent foramen ovale, 
ASD atrial septal defect, AVSD atrioventricular septal defect, EA esophageal atresia, and TEF tracheoe-
sophageal fistula
a Note infants may have multiple anomalies; therefore, figures add up to more than 100%
$ denotes value which rounds to 0.05 and, therefore, not statistically significant
Associated anomalies (n = 63a) T21 (n = 33) No chromosomal 
anomaly (n = 64)
p
Associated cardiac anomaly 30 (91) 17 (27) < 0.001
  Isolated PDA 3 (9.1) 2 (3)
  PDA with other structural cardiac anomaly 14 (42) 6 (9)
  VSD 12 (36) 5 (7.8)
  PFO 8 (24) 6 (9.4)
  ASD 8 (24) 4 (6.3)
  AVSD 4 (12) 0 (0)
  Tetralogy of fallot 2 (6.1) 1 (1.6)
  Coarctation/hypoplasia of aorta 1 (3.0) 1 (1.6)
  Other 3 (9.1) 7 (11)
Annular pancreas 1 (3.0) 11 (17.2) 0.05$
Biliary tree anomaly 0 (0) 0 (0)
Abnormal midgut rotation 7 (21) 15 (23) 1.00
Other gastrointestinal anomaly 1 (3.0) 12 (20) 0.03
  Anorectal malformation 1 (3.0) 4 (6.3)
  EA with TEF 0 (0) 5 (7.8)
  Isolated EA 0 (0) 4 (6.3)
  Meckel’s diverticulum 0 (0) 1 (1.6)
  Ileal atresia 0 (0) 2 (3.1)
  Cloaca anomaly 0 (0) 1 (1.6)
Other structural anomalies 4 (12) 12 (19) 0.41
  Renal 0 (0) 5 (7.8)
  Limb 1 (3.0) 1 (1.6)
  Spine 0 (0) 2 (3.1)
  Other 3 (9.1) 7 (11)
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chromosomal abnormality. Furthermore, infants with T21 
had a longer initial length of hospital stay.
Non-invasive prenatal testing (NIPT) has been introduced 
as a screening tool for various chromosomal anomalies 
including T21 which can be undertaken early in fetal life 
without risk to the pregnancy which is associated with the 
traditional methods such as amniocentesis [8]. Meta-analysis 
has shown that in the general obstetric population, NIPT can 
achieve a sensitivity of 95.9% and a specificity of 99.9% for 
detecting T21 [9]. Despite this relatively new technology, 
the majority of foetuses tested for chromosomal anomalies 
in this study did so via amniocentesis. Only a third of infants 
with T21 and CDO was the T21 diagnosis detected prena-
tally. This figure is lower than we might anticipate given the 
recognised association between T21 and CDO. It is possible 
that some foetuses with T21 detected prenatally were termi-
nated in utero (and, therefore, were never included in this 
study) or that families elected not to screen for T21 despite 
the presence of features suggestive of CDO. Conversely 
infants with T21 were more likely to have a diagnosis of 
CDO made antenatally than those without T21. We specu-
late that it is likely that infants with T21 had additional third 
trimester ultrasound scans, thereby providing an additional 
opportunity for CDO to be detected.
Cardiac anomalies are the most common anomaly associ-
ated with CDO, and in this study, they were seen in over 90% 
of infants with T21 which is slightly more than the 81.5% 
reported by Singh et al. in a similar study [1, 2]. Cardiac 
anomalies in T21 are reported to be present in 33–56% of 
babies, and therefore, these are more prevalent in T21 with 
CDO [10]. It is not clear from the data collected whether 
these cardiac anomalies were detected antenatally on fetal 
ultrasonography or whether these were diagnosed in the 
postnatal period. Additionally, there were two atrial septal 
defects (ASD) not identified by day 28 in this study and, 
therefore, reported at 1 year following repair of CDO. These 
findings highlight the importance of careful screening for 
cardiac anomalies with fetal ultrasonography in suspected 
babies with CDO. We would also recommend early echocar-
diography following birth in these infants, since the risk of 
congenital cardiac anomaly is particularly high.
After congenital cardiac anomalies, GI tract anoma-
lies are the second most commonly associated anomaly in 
T21, and of these, CDO is the most common type of GI 
tract anomaly. Previous data report that 2.6–14.6% of live 
births with T21 will have CDO [10–12]. Associated GI tract 
anomalies, excluding abnormal gut rotation, were rare in 
those with T21 which is similar to findings from a previous 
study [2]. Despite a recognised association between T21 and 
Hirschsprung disease, no infant in this study had both CDO 
and Hirschsprung disease.
Two previous single-centre retrospective studies have 
reported outcomes of infants with CDO and T21. One [4] 
was from a centre in Thailand including 227 patients over 
Table 3  Outcomes comparing infants with T21 to those without a chromosomal anomaly at either 28 days or 1-year post surgical repair of CDO
p values in bold indicate statistically significant
T21 trisomy 21, PN parenteral nutrition, PICC peripherally inserted central catheter, CVC central venous catheter, CDO congenital duodenal 
obstruction
a Excluded if infant died before 28-days post surgical repair or missing data
b Excluded if infant died before 1-year post surgical repair, missing data or missing 1-year follow-up
c Excluded if event status unknown at 1-year follow-up
T21 (n = 33) No chromosomal anomaly (n = 64) p
Mortality at 28 days, n (%) 2 (6.1) 0 (0) 0.11
Achieved full enteral feeds at 28 daysa, n (%) 27 (93) 53 (87) 0.49
PN at 28 days post  opa, n (%) 2 (6.5) 7 (11) 0.71
Discharged home at 28 daysa, n (%) 16 (67) 40 (78) 0.39
Standardised weight change—birth to 28 days, z score (range) − 0.37 (− 1.15-1.11) − 0.80 (− 2.34–0.53) 0.001
Mortality at 1 yearc, n (%) 4 (15) 2 (4) 0.18
Achieved full enteral feeds at 1 yearb, n (%) 20 (100) 43 (98) 1.00
Time to full enteral feeds post op, days (range) 12.5 (4–37) 13 (5–44) 0.33
PN at 1 year post  opb, n (%) 0 (0) 1 (2.0) 1.00
PN duration, days (range) 12 (2–35) 11 (2–134) 0.94
Discharged home at 1 yearb, n (%) 21 (100) 45 (100) 1.00
Inpatient stay post op, days (range) 23 (11-114) 16.5 (6–149) 0.02
Repeat surgery related to  CDOc, n (%) 1 (3.7) 4 (7.8) 0.65
PICC/CVC-related  complicationc, n (%) 7 (25) 14 (26) 1.00
Standardised weight change—birth to 1 year, z score (range) 0.68 (− 2.12 to 2.56) − 0.33 (− 2.57 to 2.23) 0.01
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a 10-year period ending in 2006 and another [2] was from 
the UK including 79 infants over an 11-year period end-
ing in 2002. In this current study, there was no difference 
detected in outcomes between those with T21 and those with 
no chromosomal anomaly except that those with T21 have 
a longer inpatient stay and that those with T21 have better 
standardised weight gain. Singh et al. found no differences 
in terms of enteral feeding, post-operative complications, 
or mortality between the two groups. They also reported a 
similar reoperation rate for reasons related to CDO (7.8% vs 
5.2% in this series). Niramis et al. in a different healthcare 
setting and era found that those with T21 were more likely to 
undergo duodenoduodenostomy than an alternate procedure 
and mortality was higher in the T21 group. Complications 
were also more frequent in the T21 group, but no informa-
tion was provided on feeding outcomes.
In this study, the difference in standardised weight-for-
age z scores has been calculated from birth to 28 days and 
1-year post surgical repair. At 28 days, standardised weight 
loss was greater in the group without chromosomal anomaly, 
and then, at 1 year, those with T21 were thriving compared 
to those without chromosomal anomaly. There are multiple 
possible explanations for this: first, there were significantly 
more associated other GI tract anomalies in the group with-
out T21 which may have influenced feeding; second, growth 
charts for those with T21 expect less weight gain than those 
without chromosomal anomaly. Additionally, it is possible 
that the prolonged hospital stay experienced by those with 
T21 resulted in increased nutritional attention. Regardless 
of the explanation for this finding, it is reassuring for parents 
and clinicians of those with T21.
A strength of this study is the use of proven surveillance 
methodology for case ascertainment and a high 1-year fol-
low-up rate (80%) [1]. Data were collected prospectively 
from multiple neonatal surgical centres over a short period 
of time and, therefore, represent contemporary practice. This 
work is limited in that we report relatively short follow-up 
(1 year), and given its observational nature, it is possible 
that some outcomes were influenced by associated anoma-
lies other than T21.
Conclusion
This national population-based study of infants with CDO 
demonstrates that infants with T21 are managed similarly to 
their counterparts without T21 and have similar, and good, 
short-term outcomes. Infants with T21 have a higher inci-
dence of cardiac anomaly and a longer length of initial hos-
pital stay, factors that may be related. These data can be used 
by clinicians for both prenatal and postnatal counselling.
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